Generic Name:
Everolimus
Project Status:
Complete
Therapeutic Area:
Pancreatic Neuroendocrine Tumour
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Afinitor
Project Line:
Reimbursement Review
Project Number:
PC0007-000
NOC Date:
Details
Strength:
2.5 mg, 5 mg and 10 mg
Tumour Type:
Gastrointestinal
Indications:
Pancreatic neuroendocrine tumours
Funding Request:
Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease.
Review Status:
Complete
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease.
pERC Meeting:
Final Recommendation Issued: